Evidence map›Paper›PMID 18835464›Full record

ArticleBone2009

CCN family 2/connective tissue growth factor (CCN2/CTGF) regulates the expression of Vegf through Hif-1alpha expression in a chondrocytic cell line, HCS-2/8, under hypoxic condition.

Takashi Nishida, Seiji Kondo, Azusa Maeda, Satoshi Kubota, Karen M Lyons, Masaharu Takigawa

Open access · greenAbstract read
In one paragraph

Article in Bone, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 44 citations in OpenAlex.

  1. Current research on the role of HIF in intervertebral disc degeneration.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Microrna-199a-5p Functions as a Tumor Suppressor via Suppressing Connective Tissue Growth Factor (CTGF) in Follicular Thyroid Carcinoma.Medical science monitor : international medical journal of experimental and clinical research · 2016
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Molecular regulation of CCN2 in the intervertebral disc: lessons learned from other connective tissues.Matrix biology : journal of the International Society for Matrix Biology · 2013
    Review
  16. Article
  17. Article
  18. Article
  19. Roles for CCN2 in normal physiological processes.Cellular and molecular life sciences : CMLS · 2011
    Review
  20. CTGF is overexpressed in papillary thyroid carcinoma and promotes the growth of papillary thyroid cancer cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2011
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Takashi NishidaDepartment of Biochemistry and Molecular Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan.
Seiji Kondo
Azusa Maeda
Satoshi Kubota
Karen M Lyons
Masaharu Takigawa
Okayama University · JPShimane University · JPUniversity of California, Los Angeles · US

Funding

CCN PROTEINS IN CARTILAGE FORMATION AND MAINTENANCER01AR052686 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LYONS, KAREN M. · 2005 to 2015
$3.9M
NIAMS NIH HHS R01 AR052686
6 · The paper itself

Abstract

Vascular endothelial growth factor (VEGF) is essential for establishing vascularization and regulating chondrocyte development and survival. We have demonstrated that VEGF regulates the expression of CCN2/connective tissue growth factor (CCN2/CTGF) an essential mediator of cartilage development and angiogenesis, suggesting that CCN2 functions in down-stream of VEGF, and that VEGF function is mediated in part by CCN2. On the other hand, the phenotype of Ccn2 mutant growth plates, which exhibit decreased expression of VEGF in the hypertrophic zone, indicates that Vegf expression is dependent on Ccn2 expression as well. Therefore, we investigated the molecular mechanisms underlying the induction of VEGF by CCN2 using a human chondrocytic cell line, HCS-2/8. Hypoxic stimulation (5% O(2)) of HCS-2/8 cells increased VEGF mRNA levels by approximately 8 fold within 6 h as compared with the cells cultured under normoxia. In addition, VEGF expression was further up-regulated under hypoxia in HCS-2/8 cells transfected with a Ccn2 expression plasmid. Hypoxia-inducible factor (HIF)-1alpha mRNA and protein levels were increased by stimulation with recombinant CCN2 (rCCN2). Furthermore, the activity of a VEGF promoter that contained a HIF-1 binding site was increased in HCS-2/8, when the cells were stimulated by rCCN2. These results suggest that CCN2 regulates the expression of VEGF at a transcriptional level by promoting HIF-1alpha activity. In fact, HIF-1alpha was detected in the nuclei of proliferative and pre-hypertrophic chondrocytes of wild-type mice, whereas it was not detected in Ccn2 mutant chondrocytes in vivo. This activation cascade from CCN2 to VEGF may therefore play a critical role in chondrocyte development and survival.

Indexed as

Gene Expression RegulationAnimalsBase SequenceCell HypoxiaCell LineCell NucleusChondrocytesConnective Tissue Growth FactorGrowth PlateHumansHypoxia-Inducible Factor 1, alpha SubunitMicePromoter Regions, GeneticProtein TransportRNA, MessengerVascular Endothelial Growth Factor AConnective Tissue Growth FactorHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitRNA, MessengerVascular Endothelial Growth Factor A

Identifiers

PMID18835464
PMCPMC2760594
OpenAlexW2006733661

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.